HTA Quarterly | Fall 2020

By Xcenda |

In this issue, our editors examine market access in South Korea, new treatments for Alzheimer's disease, new pharmaceutical policies in China, and the patient role in ICER value assessments.

HTA by the Numbers

$2,340 | $3,120

The price for a typical treatment course of remdesivir for COVID-19 for people covered by government health programs in the United States (US) and other developed countries will be $2,340; the cost will be $3,120 for US patients with private insurance. The announced pricing falls below the cost-effective price range reported by the nonprofit group Institute for Clinical and Economic Review (ICER), which reported a cost-effective price range of $4,580 to $5,080. In 127 poor or middle-income countries, Gilead is allowing generic makers to supply the drug, and two countries have announced doing so for around $600 per treatment course.


The first batches of COVID-19 vaccines should go to “people most at risk of infection,” such as medical staff on the front lines or transport sector workers, not just in all EU countries, but internationally. But “we [countries] shouldn't fight each other. We should make it available community-wise, not country-wise ... I feel strongly about this,” said Guido Rasi, head of the European Medicines Agency (EMA), speaking on the importance of a global, coordinated approach to vaccine deployment.
Read more